Giant Cell Tumor: Pathogenesis and Clinical Manifestation
Authors
Adinda Ilsa Maulida , Ali Ramzi , Amrullah Muliawan H , Baiq Ghassani Kayla , Clara Nadila , Dinda Salsabila , Febbi Anggy , Herodya Lajunee Fesmia , Jihan Alifa Rahma , Trisna Ayu Kurnia Putri , Wina Aryslia Fakar , Zulfa Hasyimiyyah Ihtisyam , Nurhidayati NurhidayatiDOI:
10.29303/jbt.v23i4b.5831Published:
2023-11-07Issue:
Vol. 23 No. 1 (2023): Special IssueKeywords:
Clinical manifestation, giant cell tumor, pathogenesis.Articles
Downloads
How to Cite
Downloads
Metrics
Abstract
A giant cell tumor of bone (GCTB) as known as a benign bone tumor (neoplasm) is aggressive locally and frequently recurs, and it is characterized by the growth of mononuclear stromal cells and datia cells that resemble osteoclasts. GCTB has varying incidence rates and has been shown to have high mortality. GCTB patients have several treatment options, but the majority of patients still experience recurrence and even metastasis to other organs. This literature review aims to explain more deeply about Giant Cell Tumor (GCT) starting from the definition, etiology, epidemiology, pathogenesis, clinical manifestations and treatment options so that patients get a better prognosis. This literature review was conducted using the keywords "Giant Cell Tumor AND pathogenesis AND clinical manifestation" from PubMed dan Google Scholar. The results of the literature review carried out are that the molecular and biological pathogenesis of GCTB consists of 4 processes, namely tumorigenesis of neoplastic mononuclear stromal cells, generation of reactive multinucleated giant cells, bone resorption/migration, and bone matrix remodeling for angiogenesis, invasiveness, and metastasis. Besides, the histological picture of GCTB contains "reactive" osteoclasts such as multinucleated giant cells (Giant Cells/GC), round cells such as macrophages and spindle stromal cells such as "neoplastic" fibroblasts (mononuclear stromal cells/SC) which are important findings in establishing the diagnosis. In conclusion, staging and management are very important to produce a better prognosis and reduce recurrence rates in GCTB patients.
References
Amelio, J. M., Rockberg, J., Hernandez, R. K., Sobocki, P., Stryker, S., Bach, B. A., Engellau, J., & Liede, A. (2016). Population-based study of giant cell tumor of bone in Sweden (1983-2011). Cancer Epidemiology, 42, 82–89. DOI: https://doi.org/10.1016/j.canep.2016.03.014
Cao, H., Lin, F., Hu, Y., Zhao, L., Yu, X., Wang, Z., Ye, Z., Wu, S., Guo, S., Zhang, G., & Wang, J. (2017). Epidemiological and Clinical Features of Primary Giant Cell Tumors of the Distal Radium: A Multicenter Retrospective Study in China. Scientific Reports, 7(1), 1–6. DOI: https://doi.org/10.1038/s41598-017-09486-6
Gestin, D., Asri, A., & Novianti, H. (2020). Metastase Giant Cell Tumour of Bone ke Paru. Jurnal Kesehatan Andalas, 9(1), 108. DOI: https://doi.org/10.25077/jka.v9i1.1256
Hartmann, W., Harder, D., & Baumhoer, D. (2021). Giant Cell-Rich Tumors of Bone. Surgical Pathology Clinics, 14(4), 695–706. DOI: https://doi.org/10.1016/j.path.2021.06.010
Júnior, R. C. L. O., Pereira, M. G. da S., Garcia, P. B. L., Santos, P. A. dos, Cavalcanti, A. dos S., & Meohas, W. (2016). Epidemiological study on giant cell tumor recurrence at the Brazilian National Institute of Traumatology and Orthopedics. Revista Brasileira de Ortopedia (English Edition), 51(4), 459–465. DOI: https://doi.org/10.1016/j.rboe.2016.06.004
Kamath, N., Agarwal, J., & Gulia, A. (2019). Axial giant cell tumor - current standard of practice. Journal of Clinical Orthopaedics and Trauma, 10(6), 1027–1032. DOI: https://doi.org/10.1016/j.jcot.2019.09.025
Kelly, D., Mc Erlean, S., Byrne, D., Mahon, P. Mac, & Mc Caffrey, J. (2016). A case of thoracic giant cell tumor of bone and discussion of radiological features and current management practices. Radiology Case Reports, 11(3), 222–226. DOI: https://doi.org/10.1016/j.radcr.2016.04.009
Kitagawa, Y., & Takai, S. (2020). Optimal treatment for tenosynovial giant cell tumor of the hand. Journal of Nippon Medical School, 87(4), 184–190. DOI: https://doi.org/10.1272/jnms.JNMS.2020_87-408
Liede, A., Hernandez, R. K., Tang, E. T., Li, C., Bennett, B., Wong, S. S., & Jandial, D. (2018). Epidemiology of benign giant cell tumor of bone in the Chinese population. Journal of Bone Oncology, 12(March), 96–100. DOI: https://doi.org/10.1016/j.jbo.2018.07.003
Lin, F., Hu, Y., Zhao, L., Zhang, H., Yu, X., Wang, Z., Ye, Z., Wu, S., Guo, S., Zhang, G., & Wang, J. (2016). The epidemiological and clinical features of primary giant cell tumor around the knee: A report from the multicenter retrospective study in China. Journal of Bone Oncology, 5(1), 38–42. DOI: https://doi.org/10.1016/j.jbo.2016.02.001
Lin, X., Liu, J., & Xu, M. (2021). The prognosis of giant cell tumor of bone and the vital risk factors that affect its postoperative recurrence: A meta-analysis. Translational Cancer Research, 10(4), 1712–1722. DOI: https://doi.org/10.21037/tcr-20-3100
Mavrogenis, A. F., Igoumenou, V. G., Megaloikonomos, P. D., Panagopoulos, G. N., Papagelopoulos, P. J., & Soucacos, P. N. (2017). Giant cell tumor of bone revisited. Sicot-J, 3. DOI: https://doi.org/10.1051/sicotj/2017041
Mohaidat, Z. M., Al-jamal, H. Z., Bany-Khalaf, A. M., Radaideh, A. M., & Audat, Z. A. (2019). Giant cell tumor of bone: Unusual features of a rare tumor. Rare Tumors, 11. DOI: https://doi.org/10.1177/2036361319878894
Montgomery, C., Couch, C., Emory, C. L., & Nicholas, R. (2018). Giant Cell Tumor of Bone: Review of Current Literature, Evaluation, and Treatment Options. Journal of Knee Surgery, 32(4), 331–336. DOI: https://doi.org/10.1055/s-0038-1675815
Nagano, A., Urakawa, H., Tanaka, K., & Ozaki, T. (2022). Current management of giant-cell tumor of bone in the denosumab era. Japanese Journal of Clinical Oncology, 52(5), 411–416. DOI: https://doi.org/10.1093/jjco/hyac018
Nakata, E., Kawai, H., Fujiwara, T., Kunisada, T., Inoue, H., Futagawa, M., Katayama, H., Itano, T., & Ozaki, T. (2022). Clinicopathological and histological analysis of secondary malignant giant cell tumors of bone without radiotherapy. Oncology Letters, 24(3), 1–13. DOI: https://doi.org/10.3892/ol.2022.13439
Noh, B. J., & Park, Y. K. (2018). Giant cell tumor of bone: updated molecular pathogenesis and tumor biology. Human Pathology, 81, 1–8. DOI: https://doi.org/10.1016/j.humpath.2018.06.017
Pradana, I. P. G. P., & Edward, M. (2021). Giant Cell Tumor of the Ribs: a Case Report. (JOINTS) Journal Orthopaedi and Traumatology Surabaya, 10(1), 32. DOI: https://doi.org/10.20473/joints.v10i1.2021.32-38
Putra, I. K. B. A., Sumadi, I. W. J., Sriwidyani, N. P., & Ekawati, N. putu. (2021). Karakteristik klinikopatologi giant cell tumor tulang di rsup sanglah denpasar bali tahun 2008 – 2018. Jurnal Medika Udayana, 10(1), 24–27.
Sobti, A., Agrawal, P., Agarwala, S., & Agarwal, M. (2016). Giant cell tumor of bone - An overview. Archives of Bone and Joint Surgery, 4(1), 2–9.
Tsukamoto, S., Mavrogenis, A. F., Kido, A., & Errani, C. (2021). Current concepts in the treatment of giant cell tumors of bone. Cancers, 13(15), 1–17. DOI: https://doi.org/10.3390/cancers13153647
Verschoor, A. J., Bovée, J. V. M. G., Mastboom, M. J. L., Sander Dijkstra, P. D., Van De Sande, M. A. J., & Gelderblom, H. (2018). Incidence and demographics of giant cell tumor of bone in The Netherlands: First nationwide Pathology Registry Study. Acta Orthopaedica, 89(5), 570–574. DOI: https://doi.org/10.1080/17453674.2018.1490987
Xu, R., & Choong, P. F. M. (2022). Metastatic giant cell tumour of bone: a narrative review of management options and approaches. ANZ Journal of Surgery, 92(4), 691–696. DOI: https://doi.org/10.1111/ans.17520
License
Copyright (c) 2023 Adinda Ilsa Maulida, Ali Ramzi, Amrullah Muliawan H, Baiq Ghassani Kayla, Clara Nadila, Dinda Salsabila, Febbi Anggy, Herodya Lajunee Fesmia, Jihan Alifa Rahma, Trisna Ayu Kurnia Putri, Wina Aryslia Fakar, Zulfa Hasyimiyyah Ihtisyam, Nurhidayati Nurhidayati
This work is licensed under a Creative Commons Attribution 4.0 International License.
Jurnal Biologi Tropis is licensed under a Creative Commons Attribution 4.0 International License.
The copyright of the received article shall be assigned to the author as the owner of the paper. The intended copyright includes the right to publish the article in various forms (including reprints). The journal maintains the publishing rights to the published articles.
Authors are permitted to disseminate published articles by sharing the link/DOI of the article at the journal. Authors are allowed to use their articles for any legal purposes deemed necessary without written permission from the journal with an acknowledgment of initial publication to this journal.